Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Alvotech - Ordinary Shares
(NQ:
ALVO
)
14.54
+0.15 (+1.04%)
Streaming Delayed Price
Updated: 9:39 AM EDT, Jun 12, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alvotech - Ordinary Shares
< Previous
1
2
3
4
Next >
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
June 12, 2023
From
Teva Pharmaceutical Industries Limited
Via
Business Wire
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®
June 12, 2023
From
Alvotech
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating RH, Alvotech, and TriplePoint and Encourages Investors to Contact the Firm
June 04, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Alvotech Investors With Losses to Inquire About Securities Class Action Investigation - ALVO, ALVOW
June 03, 2023
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Exposures
Product Safety
Alvotech to Participate in Jefferies Healthcare Conference
May 31, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
May 24, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
May 19, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
May 17, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Issues Annual Equality Report Covering 2022
May 15, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
May 10, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
May 04, 2023
From
Alvotech
Via
GlobeNewswire
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
May 03, 2023
From
Bragar Eagel & Squire
Via
GlobeNewswire
ALVO, ALVOW INVESTOR NEWS: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Alvotech Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – ALVOW
May 03, 2023
From
The Rosen Law Firm, P.A.
Via
Business Wire
Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
May 03, 2023
From
Alvotech
Via
GlobeNewswire
ALVOTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating Alvotech on Behalf of Alvotech Stockholders and Encourages Investors to Contact the Firm
April 19, 2023
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
April 19, 2023
From
Alvotech
Via
GlobeNewswire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
April 19, 2023
From
The Schall Law Firm
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Alvotech (ALVO) on Behalf of Investors
April 19, 2023
From
Law Offices of Howard G. Smith
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
April 18, 2023
From
The Schall Law Firm
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Alvotech (ALVO) on Behalf of Investors
April 18, 2023
From
Glancy Prongay & Murray LLP
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of Alvotech (ALVO) on Behalf of Investors
April 18, 2023
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Alvotech Provides Regulatory Update on AVT02 Biologics License Application
April 13, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Provides Update on Corporate Sustainability Framework
March 28, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
March 17, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
March 01, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
February 27, 2023
From
Alvotech
Via
GlobeNewswire
Settlement of Alvotech Private Share Placement Completed
February 10, 2023
From
Alvotech
Via
GlobeNewswire
EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
February 09, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech Enters Into Commercialization Agreement With Advanz Pharma for Proposed Biosimilar to Xolair® (Omalizumab)
February 06, 2023
From
Alvotech
Via
GlobeNewswire
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia
January 24, 2023
From
Alvotech
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.